Clinical Trials for Breast Cancer Vaccine to Start Soon

January 5, 2009

(ChattahBox) — Scientists hope to begin clinical trials this spring on a vaccine to prevent the recurrence of breast cancer. It’s designed to trick the body into doing something it wouldn’t naturally do — produce antibodies that fight breast cancer cells. The vaccine was developed through a decade of studying how the immune system responds to disease, said Thomas Kieber-Emmons, director of basic breast cancer research at the UAMS Winthrop P. Rockefeller Cancer Institute.

If successful, the vaccine developed at the University of Arkansas for Medical Sciences would be an additional treatment for patients, but not replace traditional treatment such as chemotherapy and radiation.

The trials will be done in phases. The first phase will last four to six months, and involve women with cancer that is actively spreading and women whose cancer has come back after going into remission. The women will receive five doses of the vaccine.

The second phase will last about a year and include women who have had breast cancer but are in remission and considered at high risk of getting it again. The women will have to have been off chemotherapy for at least six months.

After skin cancer, breast cancer’s the most common form of cancer in women, according to the centers for disease control and prevention. According to the National Cancer Institute, one out of eight women will get breast cancer.


One Response to “Clinical Trials for Breast Cancer Vaccine to Start Soon”

  1. Breast Cancer - Clinical Trials for Breast Cancer Vaccine to Start Soon : ChattahBox on January 5th, 2009 2:02 pm

    […] More here: Clinical Trials for Breast Cancer Vaccine to Start Soon : ChattahBox […]

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of - Comments are the opinions of the individuals leaving them, and not of or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.